COMMUNIQUE FROM THE ANNUAL GENERAL MEETING OF STENOCARE
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
On 20 May 2021 annual general meeting of shareholders of STENOCARE A/S, CVR no. 39024705, was held at Lund Elmer Sandager Law Firm, Kalvebod Brygge 39-41, 1560 Copenhagen V.
In accordance with the normal practice of rotation amongst the founders of the Company, Søren Kjær has not sought re-election to the Board and Rolf Steno has been elected to the Board in his place. As one of the founders of STENOCARE, Rolf has played an integral role in the Company’s development and will continue in his position of Chief Commercial Officer. His full background is availble in the “Board member for election” included with the Company’s notice for the Annual General Meeting.
The meeting also approved a change in the Company’s auditors and PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab were appointed as the new auditors of the Company.
The full agenda for the meeting with the results of the resolutions follows:
Agenda:
-
Appointment of a chairman of the meeting
- Report of the chairman of the board of directors
- Presentation of the annual report together with a resolution for its adoption
- Resolution to appropriate the profit or cover the loss
- Election of members of the board of directors
- Appointment of an auditor
- Any other business
Re. 1 Appointment of a chairman
Ulrik Bayer, attorney-at-law, was appointed chairman of the meeting.
The chairman of the meeting noted that out of a total of 912,815.92 share capital (excluding the company’s own shares) 366,147.52 were represented and out of a total of 11,410,199 voting rights 4,576,844 were represented – either in person or by a power of attorney. On this basis the chairman found that the annual general meeting was quorum. The chairman further stated that the annual general meeting was duly summoned.
Re. 2 Report of the chairman of the board of directors
The chairman of the board of directors submitted its report on the company’s operations from 1 January 2020 to 31 December 2020. The shareholders noted the report without objections.
Re. 3 Presentation of the annual report together with a resolution for its adoption
The company’s annual report for the period from 1 January 2020 to 31 December 2020 was presented together with a resolution for its adoption.
The resolution was adopted unanimously and by all votes represented.
Re. 4 Resolution to appropriate the profit or cover the loss
The annual report showed that the loss for the year amounted to DKK 11,786,282. The board of directors proposed a resolution to transfer DKK 11,786,282 to retained earnings and to pay out DKK 0 as dividends.
The resolution was adopted unanimously and by all votes represented.
Re. 5 Election of members of the board of directors
A resolution was proposed to re-elect the current chairman Marianne Wier, Jeppe Bo Petersen, Søren Melsing Frederiksen and to elect Rolf Steno as members of the board of directors.
The resolution was adopted unanimously and by all votes represented.
Re. 6 Appointment of an auditor
A resolution was proposed to appoint PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab, CVR no. 33773188, Strandvejen 44, 2900 Hellerup, as new auditor of the company.
The resolution was adopted unanimously and by all votes represented.
Re. 7 Any other business
There was no further business to be transacted.
The shareholders resolved to grant Ulrik Bayer, attorney-at-law, power of attorney to file the resolutions passed by the general meeting with the Danish Business Authority and to make such amendments to the resolutions and the documents which may prove necessary in order to obtain registration with the Danish Business Authority.
This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on May 20, 2021.
For additional information regarding STENOCARE, please contact: Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
STENOCARE’s Certified Adviser is Keswick Global AG, Phone: +43 1 740 408045, E-mail: info@keswickglobal.com
About STENOCARE A/S
STENOCARE A/S was founded in 2017 with the purpose of supplying medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.